Today’s Annual General Meeting of Lonza Group Ltd led by the Chairman of the Board of Directors, Rolf Soiron, was attended by 313 shareholders. They represented 35,9 % of the sharecapital.
The Shareholders supported all motions proposed by the Board of Directors including the extension for 2 years of the authorized capital and the appointment of the external auditors.
A dividend of CHF 2.15 per share will be paid out on 19 April 2011.
The Board members standing for re-election (Dame Julia Higgins, Gerhard Mayr, Rolf Soiron, Sir Richard Sykes, Patrick Aebischer and Peter Wilden) were all elected for a further term in office of one year.
As an additional member Jean-Daniel Gerber was newly elected to the Board of Directors.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at www.lonza.com.
For further Information
Lonza Group Ltd
Tel +41 61 316 8798
Fax +41 61 316 9798
Lonza Group Ltd
Tel +41 61 316 8540
Fax +41 61 316 9540